Immunovia and the Knight Cancer Institute at Oregon Health & Science University (OHSU) formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer.
The test called IMMray PanCan-d analyses a patient’s immune system for early signs of disease. The collaboration will also enable researchers to explore biomarkers for a number of other cancer types.
Pancreatic cancer is one of the deadliest forms of cancer, with a five-year survival rate of about 6 percent. It is the second most common cause of cancer-related deaths in the United States. When caught early, pancreatic cancer survival can be significantly improved by removing tumors surgically.
Given that patients rarely exhibit symptoms until the disease has progressed, screening tests are needed to find tumors when they are amenable to curative surgery. Screening tests that look for single biological markers of the disease are ineffective because they don’t discriminate between pancreatic cancer and less deadly conditions such as chronic pancreatitis, liver cirrhosis and other gastrointestinal cancers, as well as having a too low sensitivity vs. healthy individuals.
In contrast, Immunovia’s test platform, IMMray, creates a biological snapshot of an individual’s immune- response by analysing serum proteins that change as a sign of disease.
The OHSU Knight Cancer Institute’s scientists will help confirm the analytes used by IMMray PanCan-d by validating the test’s findings on blood samples collected from consenting patients with pancreatic ductal adenocarcinomas.
"Today´s collaboration with the OHSU Knight Cancer Institute represents a major milestone in the clinical validation and the US commercialization of Immunovia’s first test, IMMray PanCan-d, which has been developed for early diagnosis of pancreatic cancer in blood. Our goal is to establish IMMray PanCan-d as a standard amongst pancreatologists and diabetes physicians worldwide for detecting pancreatic cancer in high-risk groups much earlier than is possible today," emphasized Mats Grahn, Chief Executive Officer of Immunovia.
Immunovia sought a collaboration with the OHSU Knight Cancer Institute because of its commitment to early detection of cancer, as well as the depth of data collected on its patient samples through OHSU’s Brenden-Colson Center for Pancreatic Care, which is co-directed by OHSU’s Brett C. Sheppard, M.D., and Rosalie C. Sears, Ph.D., and the expertise of its molecular diagnostics laboratories, headed by Christopher Corless, M.D., Ph.D. The OHSU Knight Cancer Institute has plans to launch one of the first large-scale precision early detection research programs of its kind after raising $1 billion in funding.
The collaboration between Immunovia and the OHSU Knight Cancer Institute will use the Brenden-Colson Center samples together with matched controls to run a retrospective study to verify, in a U.S. population, the findings of previous studies from Europe and China. The Brenden-Colson registry blood samples were collected at time of diagnosis, before, during and after treatment. The clinical validation study will cover about 600 samples with different stages of pancreatic cancer, matched controls as well as patients with chronic pancreatitis.
After the test has been confirmed, the OHSU Knight Diagnostic Laboratories will validate it for clinical application; the laboratories are Clinical Laboratory Improvement Amendments (CLIA) certified and accredited by the College of American Pathologists (CAP).
If validated, Immunovia’s pancreatic cancer specific test, IMMray PanCan-d, could be the first blood-based test available for early and specific diagnosis of pancreatic cancer. It could provide physicians with actionable information early enough for the cancer to be removed surgically.
The OHSU Knight Cancer Institute and Immunovia plan to work on tests for other cancers using the same technology. The OHSU Knight Cancer Institute will also use the test platform to advance its work in developing precision cancer treatments and, eventually, the technology will be employed as part of its large-scale precision early detection research program.
The early detection program is made possible by the successful completion of the $1 billion Knight Cancer Challenge campaign which was launched after a $500 million pledge from Nike co-founder Phil Knight and his wife Penny.